Clinical trial
Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia
NCT01104792 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2010
- Completion date
- January 31, 2013
- Enrollment
- 752 (actual)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.